Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substantia Nigra | 14 | 2020 | 102 | 3.230 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 14 | 2014 | 52 | 2.930 |
Why?
|
| Parkinsonian Disorders | 7 | 2020 | 43 | 2.730 |
Why?
|
| Dopamine | 13 | 2019 | 474 | 1.730 |
Why?
|
| Tyrosine 3-Monooxygenase | 11 | 2020 | 71 | 1.710 |
Why?
|
| Corpus Striatum | 9 | 2019 | 279 | 1.570 |
Why?
|
| Aging | 11 | 2017 | 911 | 1.570 |
Why?
|
| Vagus Nerve Stimulation | 3 | 2020 | 61 | 1.390 |
Why?
|
| Locomotion | 5 | 2020 | 135 | 1.370 |
Why?
|
| Locus Coeruleus | 7 | 2020 | 55 | 1.290 |
Why?
|
| Glutamic Acid | 6 | 2019 | 332 | 1.270 |
Why?
|
| Dopaminergic Neurons | 4 | 2017 | 46 | 1.160 |
Why?
|
| Synaptic Transmission | 2 | 2016 | 236 | 0.930 |
Why?
|
| Motor Activity | 9 | 2015 | 621 | 0.830 |
Why?
|
| Nerve Degeneration | 5 | 2016 | 134 | 0.800 |
Why?
|
| Down Syndrome | 7 | 2019 | 120 | 0.790 |
Why?
|
| Parkinson Disease | 4 | 2019 | 272 | 0.780 |
Why?
|
| Adrenergic Neurons | 2 | 2019 | 7 | 0.770 |
Why?
|
| Neurons | 8 | 2015 | 881 | 0.760 |
Why?
|
| Animals | 41 | 2020 | 20881 | 0.730 |
Why?
|
| Receptor, trkB | 2 | 2020 | 27 | 0.720 |
Why?
|
| Disease Models, Animal | 16 | 2020 | 2550 | 0.680 |
Why?
|
| Brain-Derived Neurotrophic Factor | 5 | 2020 | 124 | 0.670 |
Why?
|
| Vagus Nerve | 1 | 2019 | 90 | 0.650 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 2 | 2016 | 26 | 0.630 |
Why?
|
| Mice | 28 | 2020 | 8474 | 0.600 |
Why?
|
| Rats, Long-Evans | 5 | 2020 | 203 | 0.560 |
Why?
|
| Neurodegenerative Diseases | 4 | 2015 | 102 | 0.550 |
Why?
|
| Methamphetamine | 2 | 2008 | 132 | 0.540 |
Why?
|
| Oxidopamine | 4 | 2020 | 42 | 0.540 |
Why?
|
| Mice, Knockout | 13 | 2020 | 1692 | 0.530 |
Why?
|
| Mice, Inbred C57BL | 12 | 2020 | 2791 | 0.520 |
Why?
|
| Mitochondria | 2 | 2017 | 643 | 0.500 |
Why?
|
| Lipopolysaccharides | 2 | 2014 | 455 | 0.480 |
Why?
|
| Neostriatum | 4 | 2019 | 60 | 0.470 |
Why?
|
| Endotoxins | 1 | 2014 | 76 | 0.460 |
Why?
|
| Mice, Transgenic | 11 | 2019 | 1033 | 0.450 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2010 | 82 | 0.440 |
Why?
|
| Norepinephrine | 5 | 2019 | 276 | 0.440 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 2 | 2008 | 7 | 0.400 |
Why?
|
| Rats | 9 | 2020 | 5300 | 0.400 |
Why?
|
| Male | 28 | 2020 | 37321 | 0.390 |
Why?
|
| Behavior, Animal | 4 | 2020 | 470 | 0.360 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2010 | 109 | 0.360 |
Why?
|
| Memory Disorders | 3 | 2019 | 111 | 0.360 |
Why?
|
| Brain | 6 | 2019 | 2176 | 0.350 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 81 | 0.330 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 154 | 0.330 |
Why?
|
| Nucleus Accumbens | 4 | 2017 | 417 | 0.330 |
Why?
|
| Cognition Disorders | 4 | 2016 | 342 | 0.330 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2008 | 22 | 0.320 |
Why?
|
| Dopamine Agents | 1 | 2008 | 56 | 0.310 |
Why?
|
| Minocycline | 1 | 2008 | 61 | 0.310 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 1174 | 0.310 |
Why?
|
| Heterozygote | 4 | 2014 | 174 | 0.310 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2019 | 92 | 0.310 |
Why?
|
| Insulin Resistance | 2 | 2020 | 241 | 0.300 |
Why?
|
| Cell Count | 5 | 2015 | 248 | 0.280 |
Why?
|
| Microfilament Proteins | 2 | 2020 | 102 | 0.280 |
Why?
|
| Hippocampus | 3 | 2019 | 471 | 0.280 |
Why?
|
| Random Allocation | 3 | 2017 | 442 | 0.260 |
Why?
|
| Memory | 4 | 2017 | 214 | 0.250 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 221 | 0.250 |
Why?
|
| Microglia | 3 | 2014 | 143 | 0.250 |
Why?
|
| Astrocytes | 3 | 2015 | 270 | 0.230 |
Why?
|
| Gene Expression | 1 | 2006 | 770 | 0.230 |
Why?
|
| Drug-Seeking Behavior | 3 | 2017 | 213 | 0.230 |
Why?
|
| Age Factors | 6 | 2016 | 1864 | 0.220 |
Why?
|
| Alzheimer Disease | 3 | 2019 | 565 | 0.220 |
Why?
|
| Cocaine | 3 | 2017 | 555 | 0.210 |
Why?
|
| Cocaine-Related Disorders | 2 | 2017 | 504 | 0.190 |
Why?
|
| Benzylamines | 2 | 2017 | 28 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 507 | 0.180 |
Why?
|
| Neural Inhibition | 1 | 2020 | 80 | 0.180 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 2 | 2017 | 51 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 79 | 0.170 |
Why?
|
| Azepines | 1 | 2019 | 15 | 0.170 |
Why?
|
| Body Weight | 3 | 2016 | 554 | 0.170 |
Why?
|
| Calpain | 1 | 2020 | 205 | 0.160 |
Why?
|
| Electric Stimulation Therapy | 1 | 2020 | 147 | 0.160 |
Why?
|
| Motor Cortex | 1 | 2020 | 158 | 0.160 |
Why?
|
| Phosphorylation | 2 | 2014 | 1200 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 290 | 0.160 |
Why?
|
| Benzamides | 1 | 2019 | 156 | 0.150 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 134 | 0.150 |
Why?
|
| Clozapine | 2 | 2015 | 46 | 0.150 |
Why?
|
| Fluorobenzenes | 1 | 2017 | 10 | 0.150 |
Why?
|
| Organelle Biogenesis | 1 | 2017 | 34 | 0.150 |
Why?
|
| Body Temperature | 2 | 2008 | 116 | 0.150 |
Why?
|
| Receptors, Serotonin | 1 | 2017 | 74 | 0.150 |
Why?
|
| Carbazoles | 1 | 2017 | 46 | 0.150 |
Why?
|
| Models, Biological | 2 | 2013 | 981 | 0.150 |
Why?
|
| Receptors, Somatotropin | 1 | 2017 | 4 | 0.150 |
Why?
|
| Extinction, Psychological | 2 | 2015 | 240 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2020 | 506 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2017 | 35 | 0.140 |
Why?
|
| Potassium Chloride | 1 | 2016 | 45 | 0.140 |
Why?
|
| Dysbindin | 1 | 2016 | 9 | 0.140 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2016 | 24 | 0.140 |
Why?
|
| Maze Learning | 5 | 2016 | 138 | 0.140 |
Why?
|
| Diet, Western | 1 | 2016 | 17 | 0.140 |
Why?
|
| Interneurons | 1 | 2017 | 70 | 0.140 |
Why?
|
| Exosomes | 1 | 2016 | 44 | 0.140 |
Why?
|
| Neurotransmitter Agents | 1 | 2016 | 102 | 0.130 |
Why?
|
| Stroke Rehabilitation | 1 | 2020 | 335 | 0.130 |
Why?
|
| Anesthetics | 1 | 2016 | 30 | 0.130 |
Why?
|
| Midazolam | 1 | 2016 | 46 | 0.130 |
Why?
|
| Indans | 1 | 2015 | 20 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 239 | 0.130 |
Why?
|
| Cognition | 2 | 2017 | 513 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2008 | 1040 | 0.130 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2015 | 10 | 0.130 |
Why?
|
| Synaptosomes | 2 | 2016 | 57 | 0.130 |
Why?
|
| Synapses | 2 | 2015 | 222 | 0.130 |
Why?
|
| Subthalamic Nucleus | 1 | 2014 | 16 | 0.120 |
Why?
|
| Kinetics | 1 | 2016 | 1047 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2016 | 122 | 0.120 |
Why?
|
| Potassium | 2 | 2014 | 168 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 65 | 0.120 |
Why?
|
| Heroin Dependence | 1 | 2014 | 23 | 0.120 |
Why?
|
| Neuroimmunomodulation | 1 | 2014 | 16 | 0.120 |
Why?
|
| Image Enhancement | 1 | 2014 | 143 | 0.120 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 39 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 114 | 0.110 |
Why?
|
| Heroin | 1 | 2014 | 49 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 167 | 0.110 |
Why?
|
| Neuroglia | 1 | 2014 | 136 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 175 | 0.110 |
Why?
|
| Obesity | 1 | 2020 | 1076 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 237 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 514 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 247 | 0.100 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 149 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 160 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2014 | 447 | 0.100 |
Why?
|
| Walking | 1 | 2013 | 241 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 48 | 0.090 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2010 | 9 | 0.090 |
Why?
|
| Synaptic Vesicles | 1 | 2010 | 18 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 742 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 1293 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 2083 | 0.090 |
Why?
|
| Cell Survival | 3 | 2008 | 901 | 0.090 |
Why?
|
| Microdialysis | 1 | 2010 | 147 | 0.090 |
Why?
|
| Extracellular Space | 1 | 2010 | 121 | 0.090 |
Why?
|
| Memantine | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cholinergic Fibers | 1 | 2010 | 27 | 0.090 |
Why?
|
| Female | 9 | 2020 | 38074 | 0.090 |
Why?
|
| Self Administration | 3 | 2017 | 419 | 0.090 |
Why?
|
| Postural Balance | 1 | 2010 | 93 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 381 | 0.090 |
Why?
|
| Conditioning, Operant | 2 | 2014 | 241 | 0.080 |
Why?
|
| Photomicrography | 1 | 2008 | 14 | 0.080 |
Why?
|
| Leukocyte Common Antigens | 1 | 2008 | 41 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2013 | 718 | 0.080 |
Why?
|
| Encephalitis | 1 | 2008 | 43 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 756 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 626 | 0.080 |
Why?
|
| Designer Drugs | 2 | 2019 | 7 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2017 | 2689 | 0.070 |
Why?
|
| Serotonin | 1 | 2007 | 144 | 0.070 |
Why?
|
| Affect | 1 | 2008 | 218 | 0.070 |
Why?
|
| Mesencephalon | 1 | 2006 | 41 | 0.070 |
Why?
|
| Urea | 1 | 2006 | 51 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2007 | 396 | 0.070 |
Why?
|
| Rats, Inbred F344 | 2 | 2016 | 104 | 0.070 |
Why?
|
| Creatinine | 1 | 2006 | 243 | 0.070 |
Why?
|
| Axons | 1 | 2006 | 139 | 0.060 |
Why?
|
| Time Factors | 1 | 2014 | 4655 | 0.060 |
Why?
|
| Ceftriaxone | 2 | 2015 | 32 | 0.060 |
Why?
|
| Pregnancy | 1 | 2010 | 2334 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 710 | 0.060 |
Why?
|
| Genotype | 1 | 2006 | 786 | 0.060 |
Why?
|
| Reward | 1 | 2005 | 201 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2004 | 75 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1046 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2017 | 128 | 0.060 |
Why?
|
| Mice, Inbred C3H | 2 | 2014 | 134 | 0.050 |
Why?
|
| Models, Animal | 2 | 2017 | 252 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1664 | 0.050 |
Why?
|
| Kidney | 1 | 2006 | 945 | 0.050 |
Why?
|
| Forelimb | 1 | 2020 | 15 | 0.050 |
Why?
|
| Adipose Tissue, White | 1 | 2020 | 7 | 0.050 |
Why?
|
| Adipose Tissue, Brown | 1 | 2020 | 8 | 0.050 |
Why?
|
| Adiponectin | 1 | 2020 | 52 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2020 | 75 | 0.040 |
Why?
|
| Leptin | 1 | 2020 | 80 | 0.040 |
Why?
|
| Fatty Liver | 1 | 2020 | 97 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 126 | 0.040 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2020 | 222 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 397 | 0.040 |
Why?
|
| Algorithms | 2 | 2014 | 1196 | 0.040 |
Why?
|
| Spatial Learning | 1 | 2017 | 12 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 44 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 59 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 11 | 0.030 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 1 | 2016 | 9 | 0.030 |
Why?
|
| tau Proteins | 1 | 2016 | 61 | 0.030 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2016 | 10 | 0.030 |
Why?
|
| Neuropathology | 1 | 2016 | 6 | 0.030 |
Why?
|
| Synapsins | 1 | 2015 | 11 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Monoamine Oxidase | 1 | 2015 | 26 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 63 | 0.030 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2015 | 30 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 242 | 0.030 |
Why?
|
| SNARE Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Calcium Channels, N-Type | 1 | 2015 | 7 | 0.030 |
Why?
|
| Humans | 5 | 2016 | 68618 | 0.030 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2015 | 23 | 0.030 |
Why?
|
| Social Behavior | 1 | 2016 | 164 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 18 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 191 | 0.030 |
Why?
|
| Central Nervous System Agents | 1 | 2015 | 37 | 0.030 |
Why?
|
| Serine | 1 | 2015 | 99 | 0.030 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2015 | 75 | 0.030 |
Why?
|
| Morpholinos | 1 | 2014 | 8 | 0.030 |
Why?
|
| Neural Pathways | 2 | 2008 | 324 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 260 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2015 | 79 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2016 | 483 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 948 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2014 | 87 | 0.030 |
Why?
|
| Aspartic Acid | 1 | 2014 | 65 | 0.030 |
Why?
|
| Actigraphy | 1 | 2013 | 28 | 0.030 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 152 | 0.030 |
Why?
|
| Head | 1 | 2013 | 59 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 415 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2015 | 291 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 765 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1745 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 317 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 291 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 368 | 0.030 |
Why?
|
| Calcium | 1 | 2016 | 929 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 1213 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 1118 | 0.020 |
Why?
|
| Cues | 1 | 2015 | 654 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1753 | 0.020 |
Why?
|
| Chromosomes, Mammalian | 1 | 2010 | 8 | 0.020 |
Why?
|
| Trisomy | 1 | 2010 | 47 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 166 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2077 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1641 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 567 | 0.020 |
Why?
|
| Presynaptic Terminals | 1 | 2008 | 34 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2008 | 68 | 0.020 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2008 | 87 | 0.020 |
Why?
|
| Growth Cones | 1 | 2006 | 6 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2006 | 122 | 0.020 |
Why?
|
| Cell Communication | 1 | 2006 | 116 | 0.020 |
Why?
|
| Sucrose | 1 | 2005 | 58 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5717 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 786 | 0.020 |
Why?
|
| Brain Tissue Transplantation | 1 | 2004 | 10 | 0.010 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 630 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 8912 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 328 | 0.010 |
Why?
|
| Depression | 1 | 2008 | 943 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 21147 | 0.010 |
Why?
|